Per saperne di più

Per chi vuole approfondire

  • ACTO onlus: “Il silenzio non è d’oro: sapere, dire, fare contro il tumore ovarico"

Riferimenti bibliografici

  • Walsh, T., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A.108(44):18032-7.
  • Alsop, K., et al. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol.;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18.
  • Hyman, DM., et al. (2012). Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer.  118(15):3703-9.
  • Bolton, KL., et al. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA,  2307(4):382-90.
  • Ledermann, J., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 15(8):852-61.
  • Iodice, S., et al. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer, 46(12):2275-84.
Partner: